These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34210822)

  • 1. Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies.
    Rossi M; Baiardi S; Teunissen CE; Quadalti C; van de Beek M; Mammana A; Stanzani-Maserati M; Van der Flier WM; Sambati L; Zenesini C; Caughey B; Capellari S; Lemstra AW; Parchi P
    Neurology; 2021 Aug; 97(9):e930-e940. PubMed ID: 34210822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
    Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
    Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies.
    Rossi M; Candelise N; Baiardi S; Capellari S; Giannini G; Orrù CD; Antelmi E; Mammana A; Hughson AG; Calandra-Buonaura G; Ladogana A; Plazzi G; Cortelli P; Caughey B; Parchi P
    Acta Neuropathol; 2020 Jul; 140(1):49-62. PubMed ID: 32342188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
    García-Ayllón MS; Monge-Argilés JA; Monge-García V; Navarrete F; Cortés-Gómez MA; Sánchez-Payá J; Manzanares J; Gasparini-Berenguer R; Leiva-Santana C; Sáez-Valero J
    J Neurochem; 2019 Jul; 150(2):218-230. PubMed ID: 31077373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
    Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
    Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
    Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
    J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Bongianni M; Ladogana A; Capaldi S; Klotz S; Baiardi S; Cagnin A; Perra D; Fiorini M; Poleggi A; Legname G; Cattaruzza T; Janes F; Tabaton M; Ghetti B; Monaco S; Kovacs GG; Parchi P; Pocchiari M; Zanusso G
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2120-2126. PubMed ID: 31599499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
    Bargar C; Wang W; Gunzler SA; LeFevre A; Wang Z; Lerner AJ; Singh N; Tatsuoka C; Appleby B; Zhu X; Xu R; Haroutunian V; Zou WQ; Ma J; Chen SG
    Acta Neuropathol Commun; 2021 Apr; 9(1):62. PubMed ID: 33827706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misfolded alpha-synuclein detection by RT-QuIC in dementia with lewy bodies: a systematic review and meta-analysis.
    Peña-Bautista C; Kumar R; Baquero M; Johansson J; Cháfer-Pericás C; Abelein A; Ferreira D
    Front Mol Biosci; 2023; 10():1193458. PubMed ID: 37266333
    [No Abstract]   [Full Text] [Related]  

  • 10. Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
    Manne S; Kondru N; Hepker M; Jin H; Anantharam V; Lewis M; Huang X; Kanthasamy A; Kanthasamy AG
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):423-435. PubMed ID: 30706414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Patients With Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease at 3 and 5 Years After Diagnosis.
    Hamilton CA; Donaghy PC; Durcan R; Ciafone J; Olsen K; Roberts G; Firbank MJ; Allan LM; Taylor JP; O'Brien JT; Thomas AJ
    Neurology; 2024 Jul; 103(2):e209499. PubMed ID: 38870460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RT-QuIC Detection of Pathological α-Synuclein in Skin Punches of Patients with Lewy Body Disease.
    Mammana A; Baiardi S; Quadalti C; Rossi M; Donadio V; Capellari S; Liguori R; Parchi P
    Mov Disord; 2021 Sep; 36(9):2173-2177. PubMed ID: 34002890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.
    Hall S; Orrù CD; Serrano GE; Galasko D; Hughson AG; Groveman BR; Adler CH; Beach TG; Caughey B; Hansson O
    Acta Neuropathol Commun; 2022 Jun; 10(1):90. PubMed ID: 35733234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression.
    van de Beek M; van Steenoven I; van der Zande JJ; Barkhof F; Teunissen CE; van der Flier WM; Lemstra AW
    Mov Disord; 2020 May; 35(5):859-867. PubMed ID: 32048343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
    van der Zande JJ; Gouw AA; van Steenoven I; van de Beek M; Scheltens P; Stam CJ; Lemstra AW
    Neurology; 2020 Aug; 95(6):e662-e670. PubMed ID: 32636325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden.
    Bentivenga GM; Mammana A; Baiardi S; Rossi M; Ticca A; Magliocchetti F; Mastrangelo A; Poleggi A; Ladogana A; Capellari S; Parchi P
    Acta Neuropathol; 2024 Jan; 147(1):18. PubMed ID: 38240849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome.
    Giannini G; Baiardi S; Dellavalle S; Zenesini C; Cevoli S; Danner N; Jyrkkänen HK; Rossi M; Polischi B; Quadalti C; Stefanini C; Cortelli P; Milletti D; Herukka SK; Palandri G; Leinonen V; Parchi P
    Fluids Barriers CNS; 2022 Sep; 19(1):71. PubMed ID: 36071460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.